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1. Introduction
Morphological and angiographic studies have demonstrated that the formation of thrombi at
sites of atherosclerotic lesions is the major cause of the development of clinical complications
of atherosclerosis, which are leading contributors to morbidity and mortality throughout the
industrialized world [1]. Thrombogenicity of the atherosclerotic plaque is determined mainly
by the stability of a fibrous cap and contents of tissue factor in its core, which activates the
coagulation cascade when exposed to flowing blood. These elements interact with each other
and with the blood vessel wall and under physiological conditions the blood flow to tissues is
unimpaired by clotting [2]. Under pathophysiological conditions, activation of blood coagu‐
lation occurs primary through interaction of platelets, vessel wall and plasma proteins (so-
called primary haemostasis). In this sense, there is evidence in the cardiology literature that
the combination of thrombolysis with antiplatelet agents speeds and augments thrombolysis
and seems to improve survival [3]. Moreover, epidemiologic studies have provided evidence
that foods (fruit and vegetables) with the experimentally proven thrombolytic/fibrinolytic
effect could reduce the risk of thrombosis [4].
This chapter discusses the involvement of coagulation and fibrinolytic system components in
thrombosis, and possible mechanisms of thrombolytic/fibrinolytic effects of natural products.
2. Coagulation and fibrinolytic system components in thrombosis
Thrombosis is associated with activation of several enzymatic cascades, including the coagu‐
lation, fibrinolysis, complement, and kinin systems. Thus, plasma markers of coagulation and
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fibrinolysis have proven to be sensitive in the initial diagnosis of acute deep venous thrombosis
[5]. Nowadays, the use of oral anticoagulants in secondary prevention is widely reported, but
inconveniences arising from the need for its stringent control and the thin line between good
therapy and incorrect therapy necessitate the search for new anticoagulants with higher
specificity and with no need for such strict controls and follow up.
Coagulation components. Coagulation is the process by which blood forms clots. It is an
important part of haemostasis; this begins almost immediately after an injury to the blood
vessel that has damaged the endothelium lining the vessel. The cessation of blood loss from a
damaged vessel begins with the junction of platelet to the subendothelial matrix and subse‐
quent activation of the coagulation system which stabilizes the platelet-rich clot and fibrin.
This process fails to stop the bleeding and begins the process of repairing a damaged vessel.
Disorders in coagulation can lead to an increased risk of bleeding (hemorrhage) or obstructive
clotting (thrombosis). For this reason there must be different mechanisms of regulation of this
phenomenon, for example serine protease inhibitors. A major class of serine protease inhibitors
regulating procoagulant enzymes is the serpin superfamily [6].
The principal inhibitor of procoagulant enzymes such as thrombin and factor Xa is the serpin
antithrombin. There are, however, other serpins that act to control coagulation enzymes, such
as heparin cofactor II (HCII), protease nexin I (PN1) and protein C inhibitor (PCI) [6]. Some
serpins act to control the action of anticoagulant enzymes, such as activated protein C. Many
of the serpins that control enzymes in the coagulation system are under the control of glyco‐
saminoglycans such as heparin, heparan sulfate and dermatan sulfate which have been found
to significantly accelerate the interaction between serpins and coagulation proteases, usually
increasing the reaction rates from values that are not relevant under physiological conditions
to rates that are relevant [5]. Another mechanism involving a serpin is the protein Z/Z-
dependent protease inhibitor (PZ/ZPI) system that inhibits activated factors X, XI and IX by
different mechanisms. ZPI is catalytically activated by PZ and in that way regulates the
function of Xa factor on the surface of the membrane. PZ joins to a binding site which is located
in the region of G helix [7]. For example, the ZPI inhibits prothrombinase activity (factor Xa
complex) in the presence of phospholipids and calcium ions, the presence of PZ enhances this
process 1000 times, but it also directly inhibits coagulation factor Xia [8]. In this same context,
it has been recently demonstrated that residues of the C and D helices of ZPI are key to the
interactions with heparin and modulate inhibitory function of serpins [9].
It has been recently demonstrated that coagulation systems may be regulated by MicroRNAs
(miRNAs) that are an abundant class of small non-coding RNAs which are regulators in a
growing number of physiological and pathological processes. However, their role in haemo‐
stasis, a complex physiological process involving a multitude of effectors, is just beginning to
be characterized. For example miR-19, miR-20, and miR-106b regulate the tissue factor
expression or it has been determined that there is an inverse correlation observed between
miR-18a and miR-19b levels with antithrombin mRNA and miR-10b that regulate the expres‐
sion of heparin. miR-15a, miR-21, miR-23b, miR-29c regulate de TFPI expression. The potential
target of these miRNAs suggests that certain miRNAs may be involved in the regulation of
selected haemostatic proteins and thereby regulate the clotting system [10, 11].
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Fibrinolytic components. Fibrinolysis is a process by which fibrin is eliminated through
activation of a blood protease cascade, and plasmin is responsible for such degradation. This
process starts with the proteolitic cleavage of the plasminogen zymogen to convert it in
plasmin through its tissue plasminogen activator (tPA) and urokinase plasminogen activa‐
tor(uPA) [5]. Plasmin acts catalytically over fibrin exposing lysine residues of the new
carboxyterminals which join to plasminogen and its activator in order to amplify fibrinolysis.
Thrombin activatable fibrinolysis inhibitor (TAFI) is a key element in this process as it is able
to control the plasmin activity by removing lysine residues in carboxyterminal region thereby
preventing positive feedback of the system. In order for TAFI to exert its action over its
substrate; it must be activated by the thrombin-thrombomodulin complex [12]. Very recently,
it has been reported that the renin-angiotensin-aldosterone system is implied in fibrinolysis
regulation; this effect is carried out through the angiotensin receptor type 1. The results of this
study demonstrate that angiotensin-1-9 favours the development of venous thrombosis in rats
decreasing the levels of plasminogen activator and increasing the levels of Plasminogen
activator inhibitor 1 (PAI-1) [13]. PAI-1 also called serpin E1 is the main inhibitor of the
plasminogen activator and it has been widely reported in the scientific literature as being
responsible for thrombotic events and recurrent foetal loss [14]. The activation of the fibrino‐
lytic system is essential to eliminate intravascular deposits of fibrin resulting from the
physiological or pathological activation of the coagulation system, but the proper functioning
of this system depends on its regulation. The fibrinolytic system is important not only in
physiological processes but also in pathological ones, such as inflammation, tumour invasion
or cardiovascular diseases.
3. Platelets and thrombolysis
The recognition of arterial thrombosis as the major causative factor in acute coronary syn‐
dromes, in particular acute myocardial infarction, was a major advance in cardiology in the
1980s [15]. Stroke is considered an independent entity by the World Health Organization
classification, the current gold standard treatment of which is the intravenous application of
thrombolytic therapy within a 4.5 h time window from the onset of stroke symptoms [16].
The main elements of thrombus include fibrin, thrombin, and platelets [17]. Current techniques
to dissolve clot focus on the fibrin and prothrombin activation, fail to address the important
effects of platelets; thrombolysis may dissolve the fibrin component of the clot but may have
no effect on the platelet portion [18]. Fibrinolytic therapy has a potent platelet aggregating
effect as does the exposure of the ruptured atherosclerotic plaque [19].
The use of thrombolytic agents, such as the recombinant tissue-type plasminogen activator (rt-
PA), is well established in the strategy for treatment of acute myocardial infarction [20]. The
insoluble fibrin fibre is hydrolyzed into fibrin degradation products by plasmin, which is
generated from plasminogen by plasminogen activators, such as t-PA, urokinase, Hageman
factor, and streptokinase plasminogen complex [21, 22].
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However, larger thrombi have notoriously proven to be resistant to intravenous tPA lysis with
recanalization rates in the range of only 13% to 20% [23]. Even if endovascular treatment of
ischemic stroke is proven to improve clinical outcomes, there will still be many patients with
residual partial or complete occlusion after intravenous tPA alone suffering ischemia, whereas
waiting for catheter rescue [24]. Thrombolysis resistance has also been demonstrated in
platelet-rich thrombi, as seen in postmortem microscopic examination of serial sections of
coronary thrombus of patients with acute myocardial infarction and sudden death revealing
that thrombus formed at the plaque fissure is very rich in platelets, whereas proximal and
distal extensions of the thrombus are composed of erythrocyte-rich material [25].
Platelet activation plays a central role in thrombus formation and can be inhibited by many
agents [26], even a weak antiplatelet agent such as aspirin is beneficial when given alone or in
conjunction with reperfusion, such therapy may improve early coronary flow rates as well as
stabilize or maintain subsequent perfusion and provide an incremental improvement in
clinical outcomes [27]. Therefore, development of combination therapies for acute ischemic
stroke that can be delivered quickly in the emergency setting is crucial. Ongoing strategies that
are in either phase II or III clinical trials include thrombin-inhibition, sonothrombolysis, and
platelet-inhibition [28].
With platelet activation, there is high affinity and binding to fibrinogen and von Willebrand
factor; in addition, there is up-regulation of further platelet activation. Activated platelets can
also facilitate thrombin generation by providing a catalytic surface and by releasing an
activated form of factor V [29], resulting in more fibrin production. In addition, exposure of
clot-bound thrombin by lytics converts more fibrinogen to fibrin, causing rethrombosis [30].
The active glycoprotein (GP) IIb/IIIa receptors bind fibrinogen, and this forms links between
platelets causing aggregation. Hence GP IIb/IIIa antagonists such as abciximab are potent
inhibitors of platelet aggregation. There is evidence in the cardiology literature that the
combination of thrombolysis with a GP IIb/IIIa antagonist speeds and augments thrombolysis
and seems to improve survival [31].
The αIIbβ3 integrin (GP IIb/IIIa) is found exclusively on platelets and megakaryocytes, with
70,000 to 90,000 receptors expressed on each platelet in the resting state. These heterodimeric
molecules have large extracellular regions for cation-facilitated ligand binding and small
intracytoplasmic tails mediating intracellular signal transduction [32]. Integrin binding affinity
is dynamic and dependent on the receptor’s conformational status. In the resting state, affinity
for fibrinogen binding is low, platelet agonists, via “inside-to-outside” signals; trigger a change
in the receptor’s structure, transforming it to a high-affinity state [33, 34].
For platelet inhibition the most commonly used antiplatelet agent is aspirin, which inhibits
platelet cyclooxygenase-1, and also, two distinct classes of antiplatelet agents with distinct
mechanisms of action, glycoprotein IIb-IIIa antagonists (e.g., abciximab, eptifibatide) and
antagonists of the platelet ADP receptor P2Y12 (e.g., clopidogrel, prasugrel), have been used
in acute coronary syndromes [35].
The advantage of blocking the GP IIb/IIIa receptor is that platelet to platelet binding through
fibrinogen or von Willebrand factor is prevented, but platelet binding to the subendothelial
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elements, that is, the surface of the damaged vessel, remains intact. An initial layer of platelets
is formed, resulting in hemostasis but not aggregation that can lead to local thrombosis or
downstream embolization to the distal microcirculation. These drugs prevent not only local
thrombosis attributable to platelet aggregation but also damage to the distal vascular bed by
platelet embolization [36].
The results of the Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute
Ischemic Stroke–Enhanced Regimen (CLEAR-ER) [37] a multicenter, double-blind, random‐
ized phase II safety trial of intravenous tPA versus eptifibatide, sought to estimate the safety
and efficacy of combination GP IIb/IIIa+reduced dose of intravenous tPA when delivered to
hyperacute ischemic stroke, demonstrating that emergent adjunctive therapies are feasible
within the first few hours of stroke onset and need to be further pursued as a means of
amplifying the thrombolysis effect of intravenous tPA [38].
Combination therapy with a local fibrinolytic and systemic GP IIb/IIIa receptor inhibitors in
the peripheral setting may represent a promising new means to accelerate reperfusion, prevent
reocclusion, allow fibrinolytic dose reductions, and improve clinical outcomes [39].
4. Thrombolytic/fibrinolytic mechanisms of natural products
Thrombolytic drugs (tPA, streptokinase (SK), and uPA) have the ability to effectively dissolve
blood clots; they differ in their detailed mechanisms in ways that alter their selectivity for fibrin
clots. The SK binds equally to circulating and non-circulating plasminogen, produces signifi‐
cant fibrinogenolysis along with clot fibrinolysis [42]. For this reason, tPA is generally
preferred as a thrombolytic agent over SK, especially when used for dissolving coronary and
cerebral vascular thrombi. Because SK is derived from streptococci, patients who have had
recent streptococci infections can require significantly higher doses of SK to produce throm‐
bolysis.
Moreover, these drugs are not used in patients who have undergone surgery or those with a
history of nervous lesions, gastrointestinal bleeding or hypertension [42]. The treatment with
tPA is limited in platelet-rich thrombi that are highly resistant to lysis by t-PA [25]. Consider‐
able efforts have been directed towards the discovery and development of natural products
from various plants which have antiplatelet [43, 44], anticoagulant [45], antithrombotic [46]
and thrombolytic activity [4]. Epidemiologic studies have provided evidence that foods with
experimentally proven antithrombotic and thrombolytic effects could reduce the risk of
thrombosis (Table 1) [47, 48, 49].
Studies from around the world have demonstrated the potent antiplatelet properties of
Ginkgo, which inhibits platelet aggregation and thrombin activity [50, 51]. The extract was
obtained by a polyphenolic method, the fibrinolytic effects of Streptokinase was compared
with those of the Ginkgo extract using a fluorometric method. The study was performed in
vitro on a labeled clot; fibrinogen was labeled with the fluorescent agent fluorescein isothio‐
cyanate and precipitated in the presence of Ca2+. The Streptokinase (100 U/mL to 1000 U/mL)
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and Ginkgo extract was added to labeled fibrin in a plasma environment. A linear relationship
was observed between the Streptokinase and Ginkgo extract [42]. The results indicate that the
effects of Ginkgo extract on the fibrinolytic system are similar to those of streptokinase [42];
hence, this herbal extract can be used as a complement to or as a substitute for streptokinase.
In this sense, there is evidence that some natural products have fibrinolytic effects.
Other researchers have found that organic extracts of six Bangladeshi plants (Ageratum
conyzoides L., Clausena suffruticosa, Leea indica (Burm.f.) Merr., Leucas aspera Willd., Senna
sophera L. Roxb., and Solanum torvum Swartz), have thrombolytic activity. An in vitro
thrombolytic model was used to check the clot lysis effect of the all these extracts [52]. The
venous blood was allowed to form clots which were weighed and treated with the extract to
disrupt the clots,the weight of clot before and after treatment provided a percentage of clot
lysis. Among the herbs studied Clausena suffruticosa, Leea indica and Leucas aspera showed a
very significant (p < 0.0001) percentage (%) of clot lysis compared to the reference drug
streptokinase (75.00 ± 3.04%) [4].
Prasad, S. et al [53] have tried six herbal preparations (Tinospora cordifolia, Rubia cordifolia,
Hemidesmus indicus, Glycyrrhiza glabra Linn, Fagonia arabica and Bacopa monnieri Linn), that have
been used since ancient times for neuroprotection and for curing vascular diseases. For
example, Hemidesmus indicus was reported to have antithrombotic activity [54] or Fagonia
arabica is known to have a blood purifying property [55]. When compared with the clot lysis
percentage obtained through water (negative control), a significant thrombolytic activity was
observed after treating the clots with Fagonia arabica and Bacopa monnieri 75.6% and 41.8% clot
lysis was obtained respectively (p value < 0.0001 &=0.0023 respectively). Chourasia, S.R. et al
[55], found the same clot lysis percentage by streptokinase as well as F. arabica.
Yamada, K. et al [56] analyzed ten onion varieties, the antithrombotic activity of which was
assessed in vivo by using a laser-induced thrombosis test in mice. Toyohira, showed significant
antithrombotic activity both in vitro and in vivo. Toyohira showed thrombolytic activity in
addition to the antiplatelet effect. Superkitamomiji, 2935A, and K83211 showed only throm‐
bolytic activity.
Natto-extracts is soybeans fermented with Bacillus subtilis, Suzuki et al [57], investigated the
effects of dietary supplementation with natto-extracts on neointima formation and on throm‐
bolysis at the site of endothelial injury. In control animals, thrombolysis started from the center
of the thrombus and mural thrombus remained attached on vessel wall. A supplementation
with natto-extracts seems to have modulated the process of thrombolysis, which started from
near the vessel walls and then thrombi detached from them.
Rajput, M.S. et al [58], explored the fibrinolytic potential of the methanolic extract of the fruits
of Lagenaria siceraria (bottle gourd), the fibrinolytic activity was expressed as percentage of
plasma clot liquefaction and was determined by plasma clot lysis at 37°C in 24 h. Treatment
of plasma clot combined with methanolic extract showed a reduction by 54.72% which was
significant when compared to the control (saline – 3.68%; p < 0.01).
Torres-Urrutia, C. et al [59] studied samples of 19 fruits and 26 vegetables. The extracts
prepared from each sample included an aqueous (juice or pressed solubles) and/or methanol-
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soluble fraction. The extracts were evaluated for antiplatelet, anticoagulant, and fibrinolytic
activity in vitro at a final concentration of 1 mg/ml, the fibrinolytic effect was determined with
the euglobin clot lysis time and fibrin plate methods. Out of all fruits and vegetables the
fibrinolytic activity was observed only in raspberries.
Bordia, A. et al [60], determined the effects of a preparation of dried garlic powder (Sapec) in
12 healthy subjects on fibrinolysis and platelet aggregation. Total euglobulin fibrinolytic
activity and t-PA activity were significantly higher 4 and 6 h after garlic and placebo ingestion.
Ginger (Zingiber officinale) is a popular food spice and it is reported to contain antihistaminic
and antioxidant factors. Verna, S.K. et al [61] studied the effect of ginger on fibrinolytic activity
on 30 healthy adult with high fat diet. The ginger increased fibrinolysis activity by 31.5% in
these patients compared with the placebo.
Morozova, E.N. et al [62]found a high fibrinolytic activity in Flammulina velutipes (also known
as the golden needle mushroom), this was compared with those of Aspergillus terricola and
Streptomyces griseusproteinases. Then Park, S.E. et al [63] purified a fibrinolytic enzyme from the
culture supernatant by ion exchange and gel filtration chromatographies. This was the first
study of fibrinolytic enzyme from mushrooms and their application as therapeutic agents.
Other researchers also have isolated different enzymes with fibrinolytic activity from mush‐
rooms [64, 65]. Also Kim et al [66], found fibrinolitic activity on Cordyceps militaris a medicinal
mushroom, their results for the fibrinolysis pattern showed that enzyme rapidly hydrolyzed
the fibrin and fibrinogen chains.
Choi, H.S et al [67], also isolated a protease with fibrinolitic properties from a Chinese herb
(Spirodela polyrhiza), the homogenate of this herb was filtered and centrifuged, the superna‐
tant was concentrated by ultrafiltration. The protease hydrolyzed not only fibrin but also
fibrinogen, cleaving Aalpha and Bbeta without affecting the gamma chain of fibrinogen. The
fibrinolytic activity was measured in the fibrin plate assay [68].
Another plant extract/product which has been identified to have fibrinolytic activity is Ananas
comosus, this has a proteolytic enzyme called bromelain, which has displayed anti-inflamma‐
tory and analgesic properties in human and laboratory studies. It has been shown to increase
fibrinolytic activity [69, 70].
Plant-derived medicines have a long history of use for the prevention and treatment of human
diseases. Advances in phytochemistry and identification of plant compounds to cure certain
diseases have renewed the interest in herbal medicines; about 30% of pharmaceuticals are
prepared from plants worldwide. Some of these plant products are modified further with
recombinant technology [71] to make them more effective and site specific. They may even be
incorporated as a thrombolytic agent for the improvement of the patients suffering from
atherothrombotic diseases [72, 73, 74, 75]. There are several thrombolytic drugs that have be
reported to have adverse side effects,, sometimes the patients died due to bleeding and
embolism [77, 78, 79, 80]. In this context, on the basis of the beneficial effects of clot dissolving
properties of plant extracts/products, these agents should be considered as a complement to
or as a substitute for thrombolytic drugs.
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Name of Compound Source Effect Mechanism of Action References
Polyphenols Ginkgo biloba Antithrombotic Fibrinolytic [42]
Terpene lactones Ginkgo biloba Antithrombotic Fibrinolytic [81]
Sterols Bacopa monnieri Linn Antithrombotic Fibrinolytic [82]
Steroidal sapogenins Lagenaria siceraria Antithrombotic Fibrinolytic [83]
Hydroxycinnamic acid Ananas comosus Antithrombotic Fibrinolytic [84]
Table 1. Natural bioactive compound with antithrombotic and fibrinolytic activities.
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